{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T19:59:01Z","timestamp":1760385541614,"version":"3.41.2"},"reference-count":50,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Theravance Biopharma Antibiotics Inc","award":["9279"],"award-info":[{"award-number":["9279"]}]},{"name":"Theravance Biopharma Antibiotics, Inc.","award":["9279"],"award-info":[{"award-number":["9279"]}]},{"name":"Theravance Biopharma Antibiotics, Inc.","award":["9279"],"award-info":[{"award-number":["9279"]}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            We first assessed telavancin (TLV) pharmacokinetics in rats after a single subcutaneous dose of 35 mg\/kg of body weight. The pharmacokinetic data were used to predict a TLV dose that simulates human exposure, and the efficacy of TLV was then evaluated using a TLV dose of 21 mg\/kg every 12 h against\n            <jats:named-content content-type=\"genus-species\">Enterococcus faecalis<\/jats:named-content>\n            OG1RF (TLV MIC of 0.06 \u03bcg\/ml) in a rat endocarditis model with an indwelling catheter. Therapy was given for 3 days with TLV, daptomycin (DAP), or ampicillin (AMP) monotherapy and with combinations of TLV plus AMP, AMP plus gentamicin (GEN), and AMP plus ceftriaxone (CRO); rats were sacrificed 24 h after the last dose. Antibiotics were given to simulate clinically relevant concentrations or as used in other studies. TLV treatment resulted in a significant decrease in bacterial burden (CFU per gram) in vegetations from 6.0 log\n            <jats:sub>10<\/jats:sub>\n            at time 0 to 3.1 log\n            <jats:sub>10<\/jats:sub>\n            after 3 days of therapy. Bacterial burdens in vegetations were also significantly lower in the TLV-treated rats than in the AMP (\n            <jats:italic>P<\/jats:italic>\n            = 0.0009)- and AMP-plus-GEN (\n            <jats:italic>P<\/jats:italic>\n            = 0.035)-treated rats but were not significantly different from that of the AMP-plus-CRO-treated rats. Bacterial burdens from vegetations in TLV monotherapy and TLV-plus-AMP-and-DAP groups were similar to each other (\n            <jats:italic>P<\/jats:italic>\n            \u2265 0.05). Our data suggest that further study of TLV as a therapeutic alternative for deep-seated infections caused by vancomycin-susceptible\n            <jats:named-content content-type=\"genus-species\">E. faecalis<\/jats:named-content>\n            is warranted.\n          <\/jats:p>","DOI":"10.1128\/aac.02489-16","type":"journal-article","created":{"date-parts":[[2017,3,21]],"date-time":"2017-03-21T00:35:18Z","timestamp":1490056518000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy of Telavancin Alone and in Combination with Ampicillin in a Rat Model of Enterococcus faecalis Endocarditis"],"prefix":"10.1128","volume":"61","author":[{"given":"Truc T.","family":"Tran","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, USA"},{"name":"UTHealth Center for Antimicrobial Resistance and Microbial Genomics, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent H.","family":"Tam","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Houston, Houston, Texas, USA"},{"name":"UTHealth Center for Antimicrobial Resistance and Microbial Genomics, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara E.","family":"Murray","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, USA"},{"name":"Department of Microbiology and Molecular Genetics, University of Texas Medical School at Houston, Houston, Texas, USA"},{"name":"UTHealth Center for Antimicrobial Resistance and Microbial Genomics, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesar A.","family":"Arias","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, USA"},{"name":"Department of Microbiology and Molecular Genetics, University of Texas Medical School at Houston, Houston, Texas, USA"},{"name":"UTHealth Center for Antimicrobial Resistance and Microbial Genomics, Houston, Texas, USA"},{"name":"Molecular Genetics and Antimicrobial Resistance Unit, Universidad El Bosque, Bogota, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kavindra V.","family":"Singh","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, USA"},{"name":"UTHealth Center for Antimicrobial Resistance and Microbial Genomics, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2008.603"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082665"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.24.3022"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp0804651"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-014-0431-z"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3051"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2015.1043889"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.14.4"},{"key":"e_1_3_2_10_2","first-page":"127","article-title":"Telavancin (vibativ), a new option for the treatment of gram-positive infections","volume":"36","author":"Plotkin P","year":"2011","unstructured":"Plotkin P PatelKUminskiAMarzellaN. 2011. Telavancin (vibativ), a new option for the treatment of gram-positive infections. P T36:127\u2013138.","journal-title":"P T"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00773-15"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00611-15"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1179\/1973947815Y.0000000050"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04616-14"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.8.3043-3050.2004"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2014.979789"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00062-10"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.8.3163-3165.2005"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01266-06"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.188.8.2875-2884.2006"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/jb.175.16.5216-5223.1993"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00856-13"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.73.8.4888-4894.2005"},{"key":"e_1_3_2_24_2","volume-title":"CLSI M100-S24","author":"CLSI","year":"2014","unstructured":"CLSI. 2014. Performance standard for antimicrobial susceptibility testing; 24th informational supplement. CLSI M100-S24. Clinical and Laboratory Standards Institute,Wayne, PA."},{"key":"e_1_3_2_25_2","volume-title":"Vibativ","author":"CTBU, Inc","year":"2014","unstructured":"CTBU, Inc. 2014. Vibativ. Telavancin insert CTBU, Inc.,South San Francisco, CA."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05002-14"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit052"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.002431"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05849-11"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00922-12"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr234"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00857-10"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq113"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365548.2014.995696"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00046-12"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000296"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg360"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.3.639"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00589-16"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2011.09.023"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ534"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.2.207"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.9.1864"},{"key":"e_1_3_2_44_2","first-page":"493","article-title":"A simple method of estimating fifty percent end points","volume":"27","author":"Reed LJ","year":"1938","unstructured":"Reed LJ MuenchH. 1938. A simple method of estimating fifty percent end points. Am J Hygiene27:493\u2013497.","journal-title":"Am J Hygiene"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.2.458"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.5.1714-1718.2003"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.10.2069"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.1.380-387.2005"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06057-11"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.1.171-177.2002"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.46.3.839-844.1984"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02489-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02489-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:39:28Z","timestamp":1645475968000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02489-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.1128\/AAC.02489-16"],"URL":"https:\/\/doi.org\/10.1128\/aac.02489-16","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"type":"print","value":"0066-4804"},{"type":"electronic","value":"1098-6596"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"2016-11-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-03-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-05-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02489-16"}}